Form 8.3 - Horizon Therapeutics plc

·9 min read

LONDON, March 23, 2023--(BUSINESS WIRE)--

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

  1. KEY INFORMATION

Name of person dealing (Note 1)

Millennium International Management LP

Company dealt in

Horizon Therapeutics plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

IE00BQPVQZ61

Date of dealing

22nd March 2023

2. INTERESTS AND SHORT POSITIONS

  1. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

5,144,274

(2.249%)

23,667

(0.010%)

(2) Derivatives (other than options)

-

-

(3) Options and agreements to purchase/sell

205,200

(0.090%)

836,700

(0.366%)

Total

5,349,474

(2.338%)

860,367

(0.376%)

b. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

Ap20

  1. DEALINGS (Note 4)

  1. Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (USD) (Note 5)

Purchase

45

108.28

Purchase

1,033

108.28

Purchase

6,607

108.23

Purchase

1,760

108.30

Purchase

400

108.27

Purchase

200

108.25

Sale

1,150

108.02

Sale

500

108.53

Sale

2,033

108.00

Sale

1,304

107.94

Purchase

168

108.32

Sale

100

108.03

Sale

40

108.07

Purchase

1,216

108.09

Sale

316

107.91

Sale

4,150

108.50

Sale

1,058

107.98

Purchase

225

108.33

Purchase

100

108.34

Sale

1,450

108.51

Purchase

507

108.35

Sale

572

107.88

Sale

300

108.52

Sale

100

107.81

Sale

1,222

107.93

Sale

102

107.75

Sale

721

107.92

Sale

989

107.96

Sale

2,000

108.01

Purchase

840

107.85

Sale

400

107.85

Sale

813

107.83

Sale

100

108.54

Sale

173

107.97

Sale

410

107.77

Sale

229

107.76

Sale

794

107.90

Purchase

160

107.84

Sale

1,043

107.89

Sale

109

108.19

Sale

352

108.15

Sale

282

108.13

Sale

141

108.05

Sale

44

107.94

Sale

14

108.04

Sale

152

108.12

Sale

396

108.32

Sale

150

108.30

Sale

109

108.22

Sale

41

108.27

Sale

813

108.06

Sale

116

108.14

Sale

936

108.09

Sale

207

108.25

Sale

361

108.18

Sale

15

108.10

Sale

3

108.17

Sale

2,312

107.78

Sale

209

107.91

Sale

360

107.99

Sale

418

108.34

Sale

162

108.26

Sale

161

108.29

Sale

303

107.73

Purchase

11,004

107.32

Sale

265

107.93

Sale

80

107.96

Sale

594

108.01

Sale

422

107.85

Sale

573

107.97

Sale

34

107.72

Sale

76

107.71

Sale

5

107.95

Sale

56

107.89

Sale

142

107.66

Sale

541

107.32

Sale

14,724

108.28

Purchase

744

108.02

Sale

1,102

108.02

Purchase

1,662

108.19

Sale

1,541

108.19

Purchase

5,610

108.15

Sale

28,092

108.15

Purchase

3,281

108.13

Sale

9,902

108.13

Purchase

3,277

108.00

Sale

1,696

108.00

Purchase

1,658

108.05

Sale

2,443

108.05

Purchase

2,150

108.23

Sale

10,882

108.23

Purchase

3,654

107.94

Sale

50

107.94

Purchase

1,100

108.04

Sale

6,638

108.04

Purchase

11,820

108.12

Sale

21,403

108.12

Purchase

45

107.67

Sale

900

107.67

Purchase

1,080

108.08

Sale

1,689

108.08

Sale

700

108.32

Purchase

4,200

108.16

Sale

6,435

108.16

Purchase

20

107.79

Sale

1,508

107.79

Purchase

9,915

108.03

Sale

2,460

108.03

Sale

2,275

108.30

Purchase

863

108.22

Sale

29,962

108.22

Purchase

5,252

108.11

Sale

25,236

108.11

Purchase

5,662

108.07

Sale

680

108.07

Purchase

791

108.21

Sale

3,867

108.21

Sale

250

108.40

Sale

2,764

108.27

Purchase

1,331

108.20

Sale

13,101

108.20

Purchase

2,521

108.06

Sale

16,154

108.06

Purchase

554

107.70

Sale

481

107.70

Purchase

1,001

108.14

Sale

4,510

108.14

Purchase

100

108.09

Sale

8,695

108.09

Sale

7,449

108.25

Purchase

440

107.82

Sale

963

107.82

Purchase

451

108.18

Sale

1,200

108.18

Purchase

1,532

108.10

Sale

4,714

108.10

Sale

1,200

108.41

Purchase

10,200

108.17

Sale

13,282

108.17

Purchase

5,524

107.78

Sale

1,986

107.78

Purchase

1,362

107.91

Sale

187

107.91

Sale

20

108.50

Purchase

3,329

107.98

Sale

379

107.98

Purchase

2,027

107.80

Sale

510

107.80

Purchase

1,183

107.99

Sale

508

107.99

Sale

2,247

108.33

Sale

5,200

108.24

Sale

120

108.56

Sale

360

108.34

Sale

533

108.51

Sale

130

108.43

Purchase

10

108.26

Sale

387

108.26

Sale

600

108.39

Sale

9,152

108.29

Sale

430

108.35

Sale

1,137

108.31

Sale

1,539

108.36

Purchase

536

107.73

Sale

191

107.73

Sale

2,089

107.81

Sale

1,700

107.32

Sale

150

108.44

Purchase

1,500

107.50

Sale

30

107.50

Sale

30

107.93

Sale

1,633

108.48

Sale

1,941

107.75

Purchase

5,914

107.92

Purchase

844

107.96

Sale

3,968

107.96

Purchase

106

107.51

Sale

480

107.51

Purchase

300

107.54

Purchase

1,474

108.01

Sale

616

108.01

Purchase

260

107.85

Sale

1,315

107.85

Sale

688

107.83

Purchase

1,900

107.48

Sale

1,928

108.37

Purchase

3,481

107.97

Sale

4,500

107.97

Purchase

4,415

107.52

Sale

189

107.52

Sale

3,115

107.86

Sale

3,575

107.72

Sale

1,595

107.62

Sale

54

107.77

Sale

2,288

107.74

Sale

816

107.71

Sale

113

107.90

Purchase

464

107.84

Sale

794

107.84

Sale

290

107.68

Purchase

600

107.95

Sale

3,429

107.95

Sale

391

107.89

Sale

1

107.45

Purchase

413

107.35

Sale

2,553

107.61

Sale

950

107.49

Sale

338

107.46

Purchase

385

107.60

Sale

1,261

107.64

Purchase

1,200

107.43

Sale

1

108.07

Sale

1

108.27

Sale

1

108.20

Sale

1

108.06

Sale

1

108.14

Sale

1

107.71

b. Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit (USD)

(Note 5)

c. Options transactions in respect of existing relevant securities

  1. Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

(USD)

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Call Option

Writing

104,400

115.00

American

5/19/2023

Call Option

Writing

100,000

115.00

American

6/16/2023

Put Option

Writing

100,000

85.00

American

6/16/2023

Put Option

Purchasing

155,000

100.00

American

6/16/2023

ii. Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

  1. Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure

23rd March 2023

Contact name

Roisin Nagle

Telephone number

+44 203 192 8746

If a connected EFM, name of offeree/offeror with which connected

If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making
disclosure:

Millennium International Management LP

Name of offeror/offeree in relation
to whose relevant securities the
disclosure relates:

Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of
relevant
security

Product
description
e.g. call
option

Written or
purchased

Number of
securities to
which option
or derivative
relates

Exercise
price
per unit

(USD)

Type
e.g.
American,
European
etc.

Expiry
date

IE00BQPVQZ61

Put Option

Purchased

1,500

90.00

American

5/19/2023

IE00BQPVQZ61

Call Option

Purchased

11,500

110.00

American

5/19/2023

IE00BQPVQZ61

Call Option

Written

262,300

115.00

American

5/19/2023

IE00BQPVQZ61

Call Option

Purchased

42,500

120.00

American

5/19/2023

IE00BQPVQZ61

Put Option

Purchased

4,300

110.00

American

5/19/2023

IE00BQPVQZ61

Put Option

Purchased

4,100

80.00

American

5/19/2023

IE00BQPVQZ61

Put Option

Purchased

400

80.00

American

1/17/2025

IE00BQPVQZ61

Put Option

Purchased

400

90.00

American

1/19/2024

IE00BQPVQZ61

Call Option

Purchased

1,200

110.00

American

8/18/2023

IE00BQPVQZ61

Call Option

Written

1,200

115.00

American

8/18/2023

IE00BQPVQZ61

Put Option

Written

50,000

80.00

American

8/18/2023

IE00BQPVQZ61

Put Option

Purchased

29,000

80.00

American

8/18/2023

IE00BQPVQZ61

Put Option

Purchased

251,600

100.00

American

5/19/2023

IE00BQPVQZ61

Put Option

Purchased

5,200

105.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Purchased

13,800

105.00

American

7/21/2023

IE00BQPVQZ61

Put Option

Purchased

7,900

105.00

American

4/21/2023

IE00BQPVQZ61

Call Option

Written

100,000

115.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Written

100,000

85.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Purchased

155,000

100.00

American

6/16/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005513/en/

Contacts

Millennium Partners, L.P.